Just my humble opinion, but could it be that the Principal Investigator has an inkling that Cohort 2 dosage level may be the Goldilocks zone?
Rather than progressing the patient to Cohort 3 dose level as originally planned, it seems that early indications are all well within the expected parameters, so it makes sense to use this patient to gradually escalate and observe if the increased dose makes a positive difference. Continuing positive results may see an early conclusion if the data is compelling.
Ann: Stable Patient in MND trial reaches 6-months on MPL, page-10
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |